[11C]BMT-136088

Drug Profile

[11C]BMT-136088

Alternative Names: BMS 986202 companion diagnostic - Bristol-Myers Squibb

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bristol-Myers Squibb
  • Class Diagnostic agents; Radiopharmaceutical diagnostics
  • Mechanism of Action Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Fibrosis; Idiopathic pulmonary fibrosis

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Fibrosis(Diagnosis) in USA (IV, Injection)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Idiopathic-pulmonary-fibrosis(Diagnosis) in USA (IV, Injection)
  • 01 Jan 2015 Bristol-Myers Squibb completes phase I trials in Idiopathic pulmonary fibrosis and Fibrosis (Diagnosis) (NCT02017730)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top